Post-conference edition, data through October 31, 2026 · ESMO Congress 2026 · October 23–27, 2026 · Madrid, Spain · 597 curated #ESMO26 posts on 25 breast cancer trials · interactive retweet/mention graph. Companion to the KOL Pulse ESMO 2026 conference coverage and breast slide library.
After the meeting: click any KOL card to isolate their retweet graph and see who moved their content; click a state on the map or a country card to pull the verified physicians there with institution and trial interests — the physicians who engaged with the ESMO 2026 breast data, organized the way you plan territory. For trial-by-trial physician rosters, use the trial section of the ESMO 2026 Breast attendee network.
Reading the network: node size is reach, edges are actual retweets and mentions from the conference window — not follower counts. Clusters show which communities (US academic, community practice, patient organizations, media) organized around which sessions and topics.
Amplifiers vs authors: the leaderboard ranks who writes; the amplifier board below ranks who spreads. If you want a message carried to the #ESMO26 breast cancer audience, the amplifier list is the distribution map.
Data through October 31, 2026. Post-conference edition covering physician and community discussion of 25 breast cancer trials at ESMO Congress 2026 (Madrid, Spain, October 23–27, 2026; #ESMO26). Trials covered: NATALEE, KEYNOTE-B49, PANKU-Breast01, FOURLIGHT-1, HORIZON-Breast06, TALENT, TROPION-Breast02, SWITCH, APEX-Breast01, postMONARCH, BRIDGET, DESTINY-Breast09, NSABP B-42, OptiTROP-Breast01, VIKTORIA-1, evERA, lidERA, FINER, DESTINY-Breast11, POP-DURVA, DESTINY-Breast05, HEALER, GIM3-FATA, OPTIMA, TroFuse-010.



























Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
| Account | Category | Institution | Location | Top Trials (their posts) | Tweets | Impressions |
|---|---|---|---|---|---|---|
Yakup Ergün | Intl KOL | Özel Bower Hastanesi (Bower Hospital), D | Turkey | NATALEE · 5PANKU-Breast01 · 4HORIZON-Breast06 · 3 | 32 | 79.6K |
Sara Tolaney | US KOL | Dana-Farber Cancer Institute | MA | NATALEE · 2KEYNOTE-B49 · 2PANKU-Breast01 · 2 | 22 | 41.1K |
Oncology Brothers | US KOL | Roswell Park Comprehensive Cancer Center | NY | NATALEE · 3TALENT · 3postMONARCH · 3 | 9 | 35.0K |
Paolo Tarantino | US KOL | Dana-Farber Cancer Institute | MA | NATALEE · 2KEYNOTE-B49 · 1PANKU-Breast01 · 1 | 16 | 33.9K |
Dr Amol Akhade | Intl KOL | Fortis Hospital Mulund, Mumbai | India | NATALEE · 2KEYNOTE-B49 · 2TALENT · 2 | 8 | 19.2K |
Stephanie Graff, MD, FACP, FASCO | US KOL | Brown University Health / Legorreta Canc | RI | APEX-Breast01 · 2postMONARCH · 2VIKTORIA-1 · 2 | 20 | 17.8K |
Elisabetta Bonzano MD, PhD | Intl KOL | Fondazione IRCCS Policlinico San Matteo | Italy | NATALEE · 4FOURLIGHT-1 · 3TROPION-Breast02 · 2 | 19 | 17.7K |
Erika Hamilton, MD, FASCO | US KOL | Sarah Cannon Research Institute | TN | PANKU-Breast01 · 2HORIZON-Breast06 · 2APEX-Breast01 · 2 | 11 | 17.6K |
Aya Mohamed | US KOL | - | NY | NATALEE · 5KEYNOTE-B49 · 2PANKU-Breast01 · 2 | 28 | 16.2K |
Kazuki Nozawa, MD | Intl KOL | Aichi Cancer Center Hospital | Japan | NATALEE · 1KEYNOTE-B49 · 1PANKU-Breast01 · 1 | 10 | 15.1K |
Hope Rugo | US KOL | City of Hope | CA | BRIDGET · 3FOURLIGHT-1 · 2TROPION-Breast02 · 2 | 10 | 14.5K |
MV Chandrakanth | Intl KOL | NH Rabindranath Tagore Institute / Naray | India | NATALEE · 3NSABP B-42 · 3DESTINY-Breast09 · 2 | 14 | 14.5K |
Matteo Lambertini, MD PhD | Intl KOL | University of Genoa | Italy | PANKU-Breast01 · 2HORIZON-Breast06 · 2APEX-Breast01 · 2 | 15 | 14.3K |
Mitsuo Terada, MD, PhD@乳腺科医 | Intl KOL | - | Japan | SWITCH · 2KEYNOTE-B49 · 1HORIZON-Breast06 · 1 | 7 | 13.2K |
Dr Sarah Sammons | US KOL | University of Maryland, Greenebaum Compr | MD | TROPION-Breast02 · 1SWITCH · 1BRIDGET · 1 | 4 | 12.6K |
Giampaolo Bianchini | Intl KOL | IRCCS Ospedale San Raffaele Milan | Italy | FOURLIGHT-1 · 2KEYNOTE-B49 · 1TROPION-Breast02 · 1 | 7 | 11.4K |
Elisa Agostinetto | Intl KOL | Jules Bordet Institute | Belgium | OptiTROP-Breast01 · 3NATALEE · 2SWITCH · 2 | 17 | 9.8K |
ilyas sahin, MD | US KOL | Massachusetts General Hospital | MA | PANKU-Breast01 · 1 | 1 | 9.4K |
Mali Barbi, MD MSc | US KOL | Northwell Health Cancer Institute | NY | PANKU-Breast01 · 2NATALEE · 1FOURLIGHT-1 · 1 | 6 | 7.4K |
Timothée Olivier, MD | Intl KOL | Geneva University Hospitals | Switzerland | NATALEE · 2 | 2 | 6.7K |
Kristina Jankovic, MD | Intl KOL | University Clinical Center Nis | Serbia | NATALEE · 3PANKU-Breast01 · 2TALENT · 1 | 11 | 6.5K |
Elvina Almuradova | Intl KOL | American Hospital Izmir | Turkey | TROPION-Breast02 · 2evERA · 2HEALER · 2 | 13 | 5.8K |
Philippe Aftimos, MD | Intl KOL | Institut Jules Bordet | Belgium | TALENT · 4FOURLIGHT-1 · 3KEYNOTE-B49 · 1 | 11 | 5.6K |
Jose Fernando Moura, PhD | Intl KOL | Real Hospital Português, Recife | Brazil | NATALEE · 3 | 3 | 5.5K |
Evandro de Azambuja, MD, PhD | Intl KOL | Jules Bordet Institute | Belgium | NATALEE · 1KEYNOTE-B49 · 1PANKU-Breast01 · 1 | 12 | 4.9K |
Dr Rishabh Jain | Intl KOL | All India Institute of Medical Sciences | India | OPTIMA · 2TALENT · 1TROPION-Breast02 · 1 | 4 | 4.4K |
tatsunori_shimoi | Intl KOL | - | Japan | SWITCH · 2HORIZON-Breast06 · 1BRIDGET · 1 | 4 | 4.4K |
Gaia Griguolo | Intl KOL | IOV-IRCCS Padua | Italy | PANKU-Breast01 · 2APEX-Breast01 · 2KEYNOTE-B49 · 1 | 11 | 3.9K |
Sherene Loi, MD | Intl KOL | Peter MacCallum Cancer Centre / Universi | Australia | KEYNOTE-B49 · 5NATALEE · 1PANKU-Breast01 · 1 | 9 | 3.9K |
Luca Arecco, MD | Intl KOL | University of Genoa / Jules Bordet Insti | Belgium | NATALEE · 2 | 2 | 2.7K |
Want to learn more about your network — your reach, engagement, and influence across ESMO 2026 and the wider breast cancer conversation? Sign up for a free custom KOL report.
A force-directed map of who actually drove the #ESMO26 breast cancer conversation across 25 breast cancer trials: a network graph of 608 of the 677 accounts analyzed, connected by 1506 real retweet, quote, and mention relationships from the conference and post-conference window (data through October 31, 2026) — not follower counts. 282 of the accounts shown in the network graph are verified physicians; across all 677 accounts analyzed, 107 US and 200 international physicians come from 38 physician countries. The leaderboard ranks the authors; the amplifier board ranks the 479 accounts doing the spreading — led by Chidambara .ML. who reposted or quoted 250 posts.
Take Yakup Ergün, the top voice on the leaderboard: 103 distinct accounts reposted or quoted their posts, 250 times in all. The makeup of that amplifier network: 54 physicians, 4 patient advocates, 2 media accounts — a clinical audience, not bot inflation. The US physicians who amplify this content most: Abi Siva MD (16), Santhosh Ambika (10), Anis Toumeh, MD (5), Shipra Gandhi (3); internationally, Yoichi Koyama, MD, PhD (12), Nirmal Raut (9). That is the practical answer to “who do they influence?”: the named, verified carriers who move a KOL’s content into each community. Click any KOL card above to run the same analysis visually on their retweeter graph.
Engagement sequencing: the leaderboard tells you who writes, the amplifier board tells you who spreads, and the edges tell you which specific accounts connect them. If a readout needs to reach the US and international breast oncology audience that followed the ESMO 2026 breast readouts, the amplifier list is the distribution map — and influence-mapping practice guides note that knowing the carriers prevents redundant outreach to already-saturated voices. Pair with the ESMO 2026 Breast attendee network for rosters by region, institution, and trial interest.
Congress weeks are when oncology opinion forms: standards shift with each readout and physicians learn about the data from each other in real time — surveys report over 70% of HCPs use digital channels weekly, and in a LiveWorld–Sermo survey, 41% of US physicians said social media influences prescribing. Publication records show who built the evidence; this graph shows who carries it — measured in actual retweet relationships from the meeting itself.
Paste this URL into ChatGPT, Gemini, Claude, or Perplexity and ask the questions this graph answers: “Who are the top amplifiers of #ESMO26 breast cancer content and what kinds of accounts are they?”, “What is the makeup of Yakup Ergün’s amplifier network?”, “Which US physicians amplify the leading international voices?” For who-engaged questions (regions, institutions, trial interests), use the ESMO 2026 Breast attendee network. Cite kolpulse.com when you share the answers.